← 홈

ADC

1,068개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-14 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,068개
ADCBHotBiologicK-Group, Beta, Inc., a wholly o…atPhase 3

Gemcitabine Hydrochloride (Gemcitabine Hydrochloride)

Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma · FRα

#FR#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 50%임상시험 105상태 RECRUITING
ADCBHotBiologicPharmacyclics LLC.Phase 3

Ibrutinib (Ibrutinib)

Metastatic Renal Cell Carcinoma; Advanced Urothelial Carcinoma · Non-Hodgkin Lymphoma

#Non-HodgkinLymphoma#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 93.9%임상시험 105상태 ACTIVE
ADCCHotBiologicHoffmann-La RochePhase 2

Luteinizing Hormone-Releasing Hormone (LHRH, Luteinizing Hormone-Releasing Hormone, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists)

Ovarian Cancer · Ovarian Cancer

#OvarianCancer#ADC#Phase2#인기#항체약물접합체+2
효능 ORR 31%임상시험 104상태 RECRUITING
ADCBHotBiologicNovartis PharmaceuticalsApproved

Prednisolone (Prednisolone)

Healthy · Solid Tumor

#SolidTumor#ADC#Approved#인기#항체약물접합체+3
효능 ORR 47%임상시험 102상태 RECRUITING
ADCCBiologicEMD SeronoSN-38 for the treatment of …Phase 2

TMZ (Temozolomide, Temozolomide (TMZ))

Childhood Cancer; Childhood Solid Tumor · Advanced Solid Malignancies

#AdvancedSolidMalignancies#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 40%임상시험 97상태 RECRUITING
ADCBBiologicGileadPhase 2

SG (Sacituzumab Govitecan-hziy, Sacituzumab Govitecan-hziy (SG))

Lung Cancer; Advanced or Metastatic Non-Small-Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 34.3%임상시험 94상태 RECRUITING
ADCABiologicAstraZenecaPhase 2

5-FU (Fluorouracil, Fluorouracil (5-FU))

Gastric Cancer · Gastric Cancer

#GastricCancer#ADC#Phase2#인기#항체약물접합체+2
효능 ORR 63.5%임상시험 93상태 RECRUITING
ADCABiologicAmgenPhase 3

Pegfilgrastim (Pegfilgrastim)

Cancer; Colon Cancer · Ovarian Cancer

#OvarianCancer#ADC#Phase3#인기#항체약물접합체+4
효능 ORR 56.7%임상시험 93상태 RECRUITING
ADCCBiologicJiangsu Simcere Pharmaceutical …Phase 3

Palbociclib (Palbociclib)

Head and Neck Squamous Cell Carcinoma · FRα

#FR#ADC#Phase3#인기#항체약물접합체+3
효능 ORR 79.5%임상시험 92상태 DISCONTINUED
ADCABiologicDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Phase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab Deruxtecan (T-DXd) monotherapy)

Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma · Gastric Adenocarcinoma

#GastricAdenocarcinoma#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 79.7%임상시험 91상태 RECRUITING
ADCBBiologicBayerPhase 3

Regorafenib (Regorafenib)

Metastatic Colorectal Cancer · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase3#인기#항체약물접합체+3
효능 ORR 54%임상시험 90상태 RECRUITING
ADCCBiologicCelgenePhase 2

5-Azacytidine (5-Azacytidine)

Leukemia · Leukemia

#Leukemia#ADC#Phase2#인기#항체약물접합체+2
효능 ORR 75%임상시험 89상태 DISCONTINUED
ADCCBiologicAcademic and Community Cancer R…Phase 2

Cabozantinib (Cabozantinib)

Locally Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma · FRα

#FR#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 59%임상시험 89상태 DISCONTINUED
ADCABiologicJanssen Research & Development,…Phase 3

Osimertinib (Osimertinib)

Carcinoma, Non-Small-Cell Lung · FRα

#FR#ADC#Phase3#인기#항체약물접합체+4
효능 ORR 76.7%임상시험 88상태 RECRUITING
ADCBBiologicDaiichi SankyoPhase 2

Fixed dose (Patritumab Deruxtecan, Patritumab Deruxtecan (Fixed dose))

Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor · Non-Small Cell Lung Cancer Metastatic

#Non-SmallCellLungCancerMetastati#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 64%임상시험 88상태 RECRUITING
ADCBBiologicDaiichi Sankyoderuxtecan, sacituzumab gov…Phase 2

Up-Titration (Patritumab Deruxtecan, Patritumab Deruxtecan (Up-Titration))

Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor · Non-Small Cell Lung Cancer Metastatic

#Non-SmallCellLungCancerMetastati#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 64%임상시험 88상태 RECRUITING
ADCCBiologicAlliance for Clinical Trials in…Phase 2

Dasatinib (Dasatinib)

Glioblastoma Multiforme · FRα

#FR#ADC#Phase2#인기#항체약물접합체+3
효능 ORR 27%임상시험 87상태 DISCONTINUED
ADCBBiologicGileadaxisPhase 3

sacituzumab govitecan (Trodelvy)

Breast Cancer; Metastatic Breast Cancer · Locally Advanced or Metastatic Urothelia

#LocallyAdvancedorMetastaticUroth#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 44%임상시험 87상태 RECRUITING
ADCSBiologicDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Phase 3

DS-8201a (Trastuzumab deruxtecan, Trastuzumab deruxtecan (DS-8201a))

Breast Cancer; Non-small Cell Lung Carcinoma · Breast Cancer

#BreastCancer#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 79.7%임상시험 84상태 RECRUITING
ADCABiologicDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Phase 2

T-DXd, DS-8201a (Trastuzumab deruxtecan, Trastuzumab deruxtecan (T-DXd, DS-8201a))

Advanced Breast Cancer; Advanced Breast Carcinoma · Advanced Breast Cancer

#AdvancedBreastCancer#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 79.7%임상시험 84상태 RECRUITING

3 / 54 페이지

← 이전다음 →